Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bray

Showing results (1031-1040 of 1,079) with videos related to

Pageof 108
Sort By:
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
BMC Public Health|June 14, 2023
CATCH-UP vaccines: protocol for a randomized controlled trial using the multiphase optimization strategy (MOST) framework to evaluate education interventions to increase COVID-19 vaccine uptake in OklahomaAmanda E Janitz, Jordan M Neil, Laura A Bray, et al.
Age (Dordrecht, Netherlands)|September 3, 2016
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose toleranceSara E Espinoza, Chen-Pin Wang, Devjit Tripathy, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Endocrine Reviews|March 9, 2018
The Science of Obesity Management: An Endocrine Society Scientific StatementGeorge A Bray, William E Heisel, Ashkan Afshin, et al.
Obesity Research|October 16, 2004
Achieving weight and activity goals among diabetes prevention program lifestyle participantsRena R Wing, Richard F Hamman, George A Bray, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2009
Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitorsPaige E Mahaney, Callain Y Kim, Richard D Coghlan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipientsRonald F Parsons, Arslan Zahid, Shalini Bumb, et al.
Journal of Medicinal Chemistry|May 14, 2010
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231)David J O'Neill, Adedayo Adedoyin, Peter D Alfinito, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 24, 2012
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factorsAramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, et al.
Pageof 108

Showing results (1031-1040 of 1,079) with videos related to

Sort By:
Pageof 108
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
BMC Public Health|June 14, 2023
CATCH-UP vaccines: protocol for a randomized controlled trial using the multiphase optimization strategy (MOST) framework to evaluate education interventions to increase COVID-19 vaccine uptake in OklahomaAmanda E Janitz, Jordan M Neil, Laura A Bray, et al.
Age (Dordrecht, Netherlands)|September 3, 2016
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose toleranceSara E Espinoza, Chen-Pin Wang, Devjit Tripathy, et al.
Diabetes, Obesity & Metabolism|April 5, 2013
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trialG A Bray, S R Smith, M A Banerji, et al.
Endocrine Reviews|March 9, 2018
The Science of Obesity Management: An Endocrine Society Scientific StatementGeorge A Bray, William E Heisel, Ashkan Afshin, et al.
Obesity Research|October 16, 2004
Achieving weight and activity goals among diabetes prevention program lifestyle participantsRena R Wing, Richard F Hamman, George A Bray, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2009
Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitorsPaige E Mahaney, Callain Y Kim, Richard D Coghlan, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 28, 2019
The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipientsRonald F Parsons, Arslan Zahid, Shalini Bumb, et al.
Journal of Medicinal Chemistry|May 14, 2010
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231)David J O'Neill, Adedayo Adedoyin, Peter D Alfinito, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 24, 2012
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factorsAramesh Saremi, Dawn C Schwenke, Thomas A Buchanan, et al.
Pageof 108